151 results on '"Reed, Eddie"'
Search Results
2. Platinum-DNA Adducts in Leukocyte DNA Correlate with Disease Response in Ovarian Cancer Patients Receiving Platinum-Based Chemotherapy
3. Biological Impact of Small Air Ions
4. Cisplatin-DNA Damage and Repair in Peripheral Blood Leukocytes in Vivo and in Vitro
5. Platinum Drug-DNA Interactions in Human Tissues Measured by Cisplatin-DNA Enzyme-Linked Immunosorbent Assay and Atomic Absorbance Spectroscopy
6. Polyclonal Antibodies to Quantitate Cis-Diamminedichloroplatinum(II)-DNA Adducts in Cancer Patients and Animal Models
7. Pharmacodynamic stimulation of thrombogenesis by angiotensin (1–7) in recurrent ovarian cancer patients receiving gemcitabine and platinum-based chemotherapy
8. Enhancement of cisplatin-induced apoptosis by β-elemene in resistant human ovarian cancer cells
9. Sensitization of lung cancer cells to cisplatin by β-elemene is mediated through blockade of cell cycle progression: antitumor efficacies of β-elemene and its synthetic analogs
10. CD44+/CD24− ovarian cancer cells demonstrate cancer stem cell properties and correlate to survival
11. Colorectal Cancer Screening Practices in Alabama: A Survey of Primary Care Physicians
12. Vascular endothelium summary statement III: Cancer prevention and control
13. Vascular endothelium summary statement VI: Research directions for the 21st century
14. Gleason score and pretreatment prostate-specific antigen in survival among patients with stage D2 prostate cancer
15. Phase II trial of carboplatin and infusional cyclosporine in platinum-resistant recurrent ovarian cancer
16. Suramin's Development: What Did we Learn?
17. Adenoviral delivery of A-FOS, an AP-1 dominant negative, selectively inhibits drug resistance in two human cancer cell lines
18. An ERCC1 splicing variant involving the 5′-UTR of the mRNA may have a transcriptional modulatory function
19. Myb overexpression overrides androgen depletion–induced cell cycle arrest and apoptosis in prostate cancer cells, and confers aggressive malignant traits: potential role in castration resistance
20. Enhancing Response Rates in Physician Surveys: The Limited Utility of Electronic Options
21. Pharmacokinetics and Relative Bioavailability of Carboxyamido-Triazole with Respect to Food and Time of Administration: Use of a Single Model for Simultaneous Determination of Changing Parameters
22. Evaluation of Cisplatin in Combination with β-Elemene as a Regimen for Prostate Cancer Chemotherapy
23. Antineoplastic effect of β-elemene on prostate cancer cells and other types of solid tumour cells
24. Ten-year follow-up of a phase 2 study of dose-intense paclitaxel with cisplatin and cyclophosphamide as initial therapy for poor-prognosis, advanced-stage epithelial ovarian cancer
25. Nucleotide excision repair and anti-cancer chemotherapy
26. Synergistic effect and possible mechanisms of tumor necrosis factor and cisplatin cytotoxicity under moderate hyperthermia against gastric cancer cells
27. A phase I/II study of continuous infusion suramin in patients with hormone-refractory prostate cancer : toxicity and response
28. Irofulven induces replication-dependent CHK2 activation related to p53 status
29. Genomic copy number changes of DNA repair genes ERCC1 and ERCC2 in human gliomas
30. Foreword: Promoting the Use of Registry-Based National Cancer Surveillance Data for Colorectal Cancer Prevention and Control
31. MZF1 possesses a repressively regulatory function in ERCC1 expression
32. Steady-state plasma concentrations and effects of taxol for a 250 mg/m2 dose in combination with granulocyte-colony stimulating factor in patients with ovarian cancer
33. Phase II Trial of Carboxyamidotriazole in Patients With Relapsed Epithelial Ovarian Cancer
34. Factors Involved in the Pharmacokinetics of COL-3, a Matrix Metalloproteinase Inhibitor, in Patients with Refractory Metastatic Cancer: Clinical and Experimental Studies
35. A Phase I/II Study of High-Dose Tamoxifen in Combination with Vinblastine in Patients with Androgen-Independent Prostate Cancer
36. Drug-Induced Lupus Associated With COL-3: Report of 3 Cases
37. Pharmacokinetics of Cisplatin Administered by Continuous Hyperthermic Peritoneal Perfusion (CHPP) to Patients with Peritoneal Carcinomatosis
38. PRELIMINARY PHARMACOKINETICS (PK) OF COL-3, A MATRIX METALLOPROTEINASE (MMP) INHIBITOR
39. Cutaneous manifestations of taxol® therapy
40. CHK2 kinase expression is down-regulated due to promoter methylation in non-small cell lung cancer
41. ALDH1A1 Maintains Ovarian Cancer Stem Cell-Like Properties by Altered Regulation of Cell Cycle Checkpoint and DNA Repair Network Signaling.
42. Gli1 contributes to cellular resistance to cisplatin through altered cellular accumulation of the drug.
43. Panepoxydone Targets NF-kB and FOXM1 to Inhibit Proliferation, Induce Apoptosis and Reverse Epithelial to Mesenchymal Transition in Breast Cancer.
44. Duration of Cisplatin Excretion in Breast Milk.
45. Are race-specific ERCC1 haplotypes in melanoma cases versus controls related to the predictive and prognostic value of ERCC1 N118N?
46. Treatment of Chemotherapy-Induced Anemia in Ovarian Cancer Patients.
47. Double Prophylaxis for Deep Venous Thrombosis in Patients With Gynecologic Oncology Who Are Undergoing Laparotomy.
48. Genetic polymorphisms in XRCC1 associated with radiation therapy in prostate cancer.
49. Apigenin inhibits VEGF and HIF-1 expression via PI3K/AKT/p70S6K1 and HDM2/p53 pathways.
50. CHK2 kinase expression is down-regulated due to promoter methylation in non-small cell lung cancer.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.